On January 8, 2015 Pfizer reported that The U.S. Food and Drug Administration (FDA) has informed Pfizer that at this time there is no plan for an Oncologic Drugs Advisory Committee meeting for IBRANCE (palbociclib) (Press release Pfizer, JAN 8, 2015, View Source [SID:1234501294]). Pfizer continues to have an open and productive dialogue with the FDA as the application for IBRANCE advances. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is April 13, 2015. The Company reports that it has entered label discussions with the FDA and hopes to be able to bring IBRANCE to patients who need it as soon as possible.